09:57 AM EST - ProMIS Neurosciences : Has initiated a program to identify novel therapeutic targets on neurotoxic strains of the protein tau, which, like neurotoxic strains of Amyloid beta, are implicated in the development of Alzheimer's disease. ProMIS Neurosciences
shares T.PMN are trading down $0.005 at $0.14.
